Company Overview and News
KUALA LUMPUR (Oct 1): Based on corporate announcements and news flow today, companies in focus on Tuesday (Oct 2) may include: AppAsia Bhd, Bioalpha Holdings Bhd, Dataprep Holdings Bhd, E.A. Technique (M) Bhd, IHH Healthcare Bhd, Malaysia Airports Holdings Bhd, Mexter Technology Bhd, Prestariang Bhd, Sealink International Bhd, Taliworks Corp Bhd, Astro Malaysia Holdings Bhd and Telekom Malaysia Bhd.
6399 5014 5145 0075 2852 0179 4863 5225 8338 MYPRY MYTEF Q0F IHHHF
KUALA LUMPUR (Oct 1): Astro Malaysia Holdings Bhd has teamed up with beIN Sports to offer live coverage of the UEFA Champion League (UCL) and UEFA Europa League (UEL) from the 2018/19 season to 2020/21.
KUALA LUMPUR, Sept 30 — An Umno delegate today accused news channel Astro Awani as being Pakatan Harapan (PH) sympathisers, calling it “worse than TV3” as he called for party members to turn to “pro-Umno media” instead.
KUALA LUMPUR (Sept 27): The FBM KLCI slipped back to below the 1,800-point level at midday break today, as sellers overtook buyers at the local bourse.
HLFBF 7113 7158 BATS TPGVF 4162 2089 5199 5347 7668 TNABY AXXTF 2836 HIPEF 1929 UPBMF 1082 6399 1163 5202 8311 2593 TGLVY 5139 0900 6888 TNABF 3719
KUALA LUMPUR: Astro Malaysia Holdings Bhd has just secured the English Premier League (EPL) broadcast rights in Malaysia for another three seasons from 2019/20 to 2021/22, but this news might not be able to cheer its shareholders given its latest disappointing quarterly results.
KUALA LUMPUR (Sept 27): Astro Malaysia Holdings Bhd shares fell 5.42% in early trade this morning after its net profit for the second quarter ended July 31, 2018 (2QFY19) sank by 93.3% to RM16.6 million, from RM246.3 million in a year ago due to the FIFA World Cup and higher cost of merchandise sales and net finance costs.
Broadcasting rights: Astro has exclusive broadcasting rights to the English Premier League for the next three seasons. — Reuters
KUALA LUMPUR (Sept 27): CIMB IB Research has downgraded Astro Malaysia Holdings Bhd to “Hold” at RM1.66 with a lower target price of RM1.75 (from RM2.70) and said Astro’s 1HFY1/19 core net profit missed expectations, at 34%/33% of house/consensus FY19 forecasts due to higher-than-expected FIFA World Cup cost in 2QFY19.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...